[{"id":"8a617f1a-04a1-44fa-9406-0c4b9b9170e3","acronym":"BEAUTY","url":"https://clinicaltrials.gov/study/NCT03979508","created_at":"2021-01-18T19:34:12.469Z","updated_at":"2024-07-02T16:35:07.182Z","phase":"Phase 2","brief_title":"Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer","source_id_and_acronym":"NCT03979508 - BEAUTY","lead_sponsor":"Mayo Clinic","biomarkers":" HER-2 • ER • PGR • CD20 • JAK2 • CD8 • CDH1 • CCR4 • IL2RA • PTPRC • NCAM1 • CCR5 • CCR7 • CD14 • CD27 • GZMB • HLA-B • NLRC5 • FOXP3 • IKZF2 • IL3RA • STAT1 • CXCR3 • CXCR5 • ITGAX • PRF1 • SNAI2 • TAP1 • CCR6 • CEACAM8 • DDX58 • HLA-C • IFNL1 • IFNL2 • IFNL3 • ITGB1 • KLRB1","pipe":" | ","alterations":" JAK2 amplification","tags":["HER-2 • ER • PGR • CD20 • JAK2 • CD8 • CDH1 • CCR4 • IL2RA • PTPRC • NCAM1 • CCR5 • CCR7 • CD14 • CD27 • GZMB • HLA-B • NLRC5 • FOXP3 • IKZF2 • IL3RA • STAT1 • CXCR3 • CXCR5 • ITGAX • PRF1 • SNAI2 • TAP1 • CCR6 • CEACAM8 • DDX58 • HLA-C • IFNL1 • IFNL2 • IFNL3 • ITGB1 • KLRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 01/10/2020","start_date":" 01/10/2020","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 07/31/2024","study_completion_date":" 07/31/2024","last_update_posted":"2024-04-29"},{"id":"d7250f67-4645-4aee-9249-1bb54b6cd454","acronym":"TANOs","url":"https://clinicaltrials.gov/study/NCT04867421","created_at":"2021-04-30T11:55:07.437Z","updated_at":"2024-07-02T16:36:09.921Z","phase":"","brief_title":"Neutrophils in Bone Sarcomas","source_id_and_acronym":"NCT04867421 - TANOs","lead_sponsor":"Université de Reims Champagne-Ardenne","biomarkers":" PD-L1 • CD8 • CD163 • PTPRC • CCR5 • CD80 • CEACAM8","pipe":"","alterations":" ","tags":["PD-L1 • CD8 • CD163 • PTPRC • CCR5 • CD80 • CEACAM8"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 09/01/2020","start_date":" 09/01/2020","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2022-05-25"},{"id":"26365345-1570-49ca-8578-b67aa79e6819","acronym":"","url":"https://clinicaltrials.gov/study/NCT03397186","created_at":"2021-01-18T16:45:56.830Z","updated_at":"2024-07-02T16:36:55.814Z","phase":"Phase 2","brief_title":"Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma","source_id_and_acronym":"NCT03397186","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" CD8 • LAG3 • CTLA4 • CD4 • CCR5 • CXCR3","pipe":" | ","alterations":" CCR5 expression","tags":["CD8 • LAG3 • CTLA4 • CD4 • CCR5 • CXCR3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCR5 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yondelis (trabectedin)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 06/19/2018","start_date":" 06/19/2018","primary_txt":" Primary completion: 01/01/2021","primary_completion_date":" 01/01/2021","study_txt":" Completion: 05/01/2021","study_completion_date":" 05/01/2021","last_update_posted":"2019-09-10"}]